Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBANASDAQ:MRNSNASDAQ:PBYINASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.58+0.6%$2.63$0.80▼$4.08$934.98M0.853.18 million shs3.53 million shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.82 million shs260 shsPBYIPuma Biotechnology$3.45+3.0%$3.19$2.23▼$4.13$171.23M1.29443,734 shs228,779 shsURGNUroGen Pharma$14.34+19.2%$8.63$3.42▼$19.01$554.67M0.41.01 million shs8.78 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+0.56%-6.53%+37.16%+40.39%+234.58%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-62.52%PBYIPuma Biotechnology+2.99%-4.17%+1.77%+3.29%+10.93%URGNUroGen Pharma+19.20%+104.27%+96.17%+24.37%-25.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.0186 of 5 stars3.62.00.04.03.10.80.6MRNSMarinus Pharmaceuticals2.1793 of 5 stars3.20.00.04.20.61.70.6PBYIPuma Biotechnology4.0103 of 5 stars3.52.00.00.02.43.33.1URGNUroGen Pharma4.6992 of 5 stars4.54.00.04.52.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7588.55% UpsideMRNSMarinus Pharmaceuticals 2.40Hold$4.79771.56% UpsidePBYIPuma Biotechnology 3.00Buy$7.00102.90% UpsideURGNUroGen Pharma 3.00Buy$32.86129.13% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, URGN, PBYI, and MRNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.006/13/2025URGNUroGen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$16.006/13/2025URGNUroGen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Buy$31.006/13/2025URGNUroGen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/13/2025URGNUroGen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.006/13/2025URGNUroGen PharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $30.006/12/2025URGNUroGen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.006/3/2025URGNUroGen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.005/23/2025URGNUroGen PharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $15.005/22/2025URGNUroGen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $3.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$184.91M5.08N/AN/A($0.16) per share-22.38MRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77PBYIPuma Biotechnology$232.71M0.74$0.82 per share4.19$1.12 per share3.08URGNUroGen Pharma$91.87M7.20N/AN/A($2.78) per share-5.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%8/6/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)PBYIPuma Biotechnology$21.59M$0.777.199.08N/A9.56%41.60%10.71%7/30/2025 (Estimated)URGNUroGen Pharma-$102.24M-$3.18N/AN/AN/A-129.11%N/A-47.94%8/12/2025 (Estimated)Latest AKBA, URGN, PBYI, and MRNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025URGNUroGen Pharma-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.521.21MRNSMarinus PharmaceuticalsN/A1.661.47PBYIPuma Biotechnology0.461.421.40URGNUroGen Pharma4.779.008.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%MRNSMarinus Pharmaceuticals98.80%PBYIPuma Biotechnology61.29%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%MRNSMarinus Pharmaceuticals5.46%PBYIPuma Biotechnology23.30%URGNUroGen Pharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million209.24 millionOptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionablePBYIPuma Biotechnology20049.63 million37.45 millionOptionableURGNUroGen Pharma20046.11 million22.26 millionOptionableAKBA, URGN, PBYI, and MRNS HeadlinesRecent News About These CompaniesUroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in MayJune 17 at 3:57 AM | marketbeat.comUroGen Pharma (NASDAQ:URGN) Sees Strong Trading Volume on Analyst UpgradeJune 17 at 1:08 AM | americanbankingnews.comURGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered LossesJune 16 at 3:46 PM | accessnewswire.comInvestors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGNJune 16 at 1:27 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGNJune 16 at 1:00 PM | accessnewswire.comUroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst UpgradeJune 16 at 10:42 AM | marketbeat.comLost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class ActionJune 16 at 10:40 AM | accessnewswire.comURGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law FirmJune 16 at 10:38 AM | prnewswire.comDid You Lose Money on UroGen Pharma Ltd. (URGN)? Levi & Korsinsky Urges Investors to Act Before July 28, 2025June 16 at 10:25 AM | accessnewswire.comUroGen Pharma (NASDAQ:URGN) Stock Rating Upgraded by HC WainwrightJune 16 at 8:17 AM | marketbeat.comURGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)June 16 at 8:17 AM | globenewswire.comUROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UroGen Pharma Ltd.June 16 at 8:15 AM | globenewswire.comJuly 28, 2025 Deadline Approaching: Join Class Action Against UroGen Pharma Ltd. (URGN) - Contact Levi & KorsinskyJune 16 at 7:35 AM | accessnewswire.comURGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!June 16 at 7:00 AM | accessnewswire.comUroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. ...June 16 at 6:24 AM | gurufocus.comUroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd.June 16 at 5:45 AM | prnewswire.comSG Americas Securities LLC Buys 142,245 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)June 16 at 3:48 AM | marketbeat.comUroGen Pharma (NASDAQ:URGN) Price Target Raised to $30.00June 16 at 1:31 AM | americanbankingnews.comUroGen Pharma (NASDAQ:URGN) Price Target Raised to $47.00June 16 at 1:31 AM | americanbankingnews.comLost Money on UroGen Pharma Ltd. (URGN)? Join Class Action Before July 28, 2025 - Contact Levi & KorsinskyJune 15 at 11:00 PM | accessnewswire.comURGN ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against UroGen Pharma Ltd. - July 28, 2025 DeadlineJune 15 at 10:55 AM | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, URGN, PBYI, and MRNS Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.58 +0.02 (+0.56%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$3.60 +0.02 (+0.42%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Puma Biotechnology NASDAQ:PBYI$3.45 +0.10 (+2.99%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$3.44 -0.01 (-0.14%) As of 06/16/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.UroGen Pharma NASDAQ:URGN$14.34 +2.31 (+19.20%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$14.20 -0.14 (-0.94%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
